ACA
CUE icon

American Capital Advisory’s Cue Biopharma CUE Stock Holding History

American Capital Advisory’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33
Closed -$2.64K – 487
2024
Q2 		$2.64K Hold
33
– – ﹤0.01% 343
2024
Q1 		$3.57K Hold
33
– – ﹤0.01% 330
2023
Q4 		$2.64K Buy
+33
New +$2.36K ﹤0.01% 343

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

American Capital Advisory's CUE Position: Q3 2024 in Review

American Capital Advisory sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 33 shares — an estimated $2.64K sold.

American Capital Advisory first reported a position in CUE in Q4 2023 and held it in 3 quarters. The position peaked at $3.57K in Q1 2024. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • American Capital Advisory reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • American Capital Advisory sold 33 Cue Biopharma shares in Q3 2024, an estimated $2.64K.
  • American Capital Advisory first reported a position in Cue Biopharma in Q4 2023 and held it in 3 quarters.
  • American Capital Advisory's Cue Biopharma position peaked at $3.57K in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on American Capital Advisory's 13F filing for Q3 2024, filed 30 Oct 2024.